🧠 Precision, Prevention, Progress: Low-Dose Aspirin for PI3K-Altered Localized Colorectal Cancer

Dr RR Baliga's "Got Knowledge Doc" Podkast

Content provided by MasterMedFacts LLC, Dr RR Baliga, MD, and MBA. All podcast content including episodes, graphics, and podcast descriptions are uploaded and provided directly by MasterMedFacts LLC, Dr RR Baliga, MD, and MBA or their podcast platform partner. If you believe someone is using your copyrighted work without your permission, you can follow the process outlined here https://podcastplayer.com/legal.

3d ago 6:31

MP4•Episode home

🚨 New in NEJM — The ALASCCA Trial 🧬

Low-dose aspirin (160 mg/day) reduced colorectal cancer recurrence in patients with PIK3CA, PIK3R1, or PTEN mutations 🎯

✅ 3-year recurrence: 7.7% (aspirin) vs 14–17% (placebo)

✅ Group A HR: 0.49 | Group B HR: 0.42

✅ NNT as low as 6 in stage III rectal cancer 💥

⚠️ Slight increase in adverse events

🧠 Editorial calls it a new standard of care:

🔬 Genotype early + 💊 Start aspirin early = 📉 Lower recurrence

📖 Read both the trial and editorial in NEJM, Sept 2025

#ColorectalCancer #PrecisionOncology #Aspirin #PIK3CA #NEJM #OncologyTrials #Genomics #AdjuvantTherapy #ALASCCA #ClinicalTrials

757 episodes